Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Feb;54(2):90-3.
doi: 10.3345/kjp.2011.54.2.90. Epub 2011 Feb 28.

A case of pseudohypoaldosteronism type 1 with a mutation in the mineralocorticoid receptor gene

Affiliations

A case of pseudohypoaldosteronism type 1 with a mutation in the mineralocorticoid receptor gene

Se Eun Lee et al. Korean J Pediatr. 2011 Feb.

Abstract

Pseudohypoaldosteronism type 1 (PHA1) is a rare form of mineralocorticoid resistance characterized in newborns by salt wasting with dehydration, hyperkalemia and failure to thrive. This disease is heterogeneous in etiology and includes autosomal dominant PHA1 owing to mutations of the NR3C2 gene encoding the mineralocorticoid receptor, autosomal recessive PHA1 due to mutations of the epithelial sodium channel (ENaC) gene, and secondary PHA1 associated with urinary tract diseases. Amongst these diseases, autosomal dominant PHA1 shows has manifestations restricted to renal tubules including a mild salt loss during infancy and that shows a gradual improvement with advancing age. Here, we report a neonatal case of PHA1 with a NR3C2 gene mutation (a heterozygous c.2146_2147insG in exon 5), in which the patient showed failure to thrive, hyponatremia, hyperkalemia, and elevated plasma renin and aldosterone levels. This is the first case of pseudohypoaldosteronism type 1 confirmed by genetic analysis in Korea.

Keywords: Infant; Mineralocorticoid; NR3C2 gene; Pseudohypoaldosteronism; Receptor.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Partial sequencing data of the NR3C2 gene of the patient and his parents. The patient had a heterozygous c.2146_2147insG (p.E716GfsX28) mutation in exon 5 of the NR3C2 gene (panel A, 5'>3' sense sequences; panel B, 3'>5' complementary sequences). His parents (panel C, his mother; panel D, his father) did not have the insertion mutation.

Similar articles

Cited by

References

    1. Sartorato P, Khaldi Y, Lapeyraque AL, Armanini D, Kuhnle U, Salomon R, et al. Inactivating mutations of the mineralocorticoid receptor in Type I pseudohypoaldosteronism. Mol Cell Endocrinol. 2004;217:119–125. - PubMed
    1. Geller DS. Mineralocorticoid resistance. Clin Endocrinol (Oxf) 2005;62:513–520. - PubMed
    1. Hanukoglu A. Type I pseudohypoaldosteronism includes two clinically and genetically distinct entities with either renal or multiple target organ defects. J Clin Endocrinol Metab. 1991;73:936–944. - PubMed
    1. Geller DS, Rodriguez-Soriano J, Vallo Boado A, Schifter S, Bayer M, Chang SS, et al. Mutations in the mineralocorticoid receptor gene cause autosomal dominant pseudohypoaldosteronism type I. Nat Genet. 1998;19:279–281. - PubMed
    1. Kwon YS, Shin HG, Ahn MS, Kim HB. A case of pseudohypoaldosteronism. J Korean Pediatr Soc. 1992;35:984–988.

LinkOut - more resources